About Verona Pharma Plc
Verona Pharma plc is a specialist pharma company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its lead drug, RPL554, a Phosphodiesterase 3 (PDE3)/PDE4 inhibitor with both bronchodilator and anti-inflammatory activities, is in Phase II trials as a nebulized treatment for acute exacerbations of COPD in a hospital setting. The Company is also exploring the potential of the drug in cystic fibrosis, where it is in pre-clinical testing. Its VRP700 is in the clinical-stage. VRP700 is a potential anti-tussive (cough) drug. It carried out a pilot study, in which an inhaled dose of VRP700 inhibited coughing in a group of patients with chronic intractable cough due to underlying lung disease. The Company also carried out a clinical study to evaluate the efficacy of an inhaled dose of VRP700 in patients with chronic intractable cough.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Exchange: LON
- Symbol: VRP
- CUSIP:
Key Metrics:
- Previous Close: $0.04
- 50 Day Moving Average: $3.178
- 200 Day Moving Average: $3.280
- 52-Week Range: £10,099,230 - GBX 2.17
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Market Cap: $33.07M
- Outstanding Shares: 1,009,923,000
Additional Links:
Consensus Ratings for Verona Pharma Plc (LON:VRP) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Verona Pharma Plc (LON:VRP)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 1/28/2016 | N+1 Singer | Reiterated Rating | Corporate | |  |
(Data available from 9/25/2014 forward)
Earnings History for Verona Pharma Plc (LON:VRP)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Verona Pharma Plc (LON:VRP)Current Year EPS Consensus Estimate: $-0.510 EPS
Dividend History for Verona Pharma Plc (LON:VRP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Verona Pharma Plc (LON:VRP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/9/2016 | Jan-Anders Karlsson,Sven | Insider | Buy | 600,000 | GBX 3 | £18,000 | |
| 1/20/2016 | Ebsworth,David | Insider | Buy | 400,000 | GBX 3 | £12,000 | |
| 12/3/2015 | Ebsworth,David | Insider | Buy | 370,000 | GBX 3 | £11,100 | |
| 6/17/2015 | David Ebsworth | Insider | Buy | 250,000 | GBX 4.70 | £11,750 | |
| 5/18/2015 | David Ebsworth | Insider | Buy | 300,000 | GBX 3.50 | £10,500 | |
| 3/3/2015 | David Ebsworth | Insider | Buy | 450,000 | GBX 2.43 | £10,935 | |
| 2/16/2015 | Biresh Roy | Insider | Buy | 500,000 | GBX 2.30 | £11,500 | |
| 2/13/2015 | Sven Jan-Anders Karlsson | Insider | Buy | 1,025,909 | GBX 2 | £20,518.18 | |
| 2/4/2015 | David Ebsworth | Insider | Buy | 700,000 | GBX 1.54 | £10,780 | |
| 1/19/2015 | Stuart Bottomly | Insider | Buy | 1,000,000 | GBX 1.50 | £15,000 | |
| 1/13/2015 | David Ebsworth | Insider | Buy | 803,107 | GBX 1.35 | £10,841.94 | |
(Data available from 1/1/2013 forward)
Latest Headlines for Verona Pharma Plc (LON:VRP)
